🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524511-36-00
Authorised Phase II

Impact of epilepsy on the brainstem adenosine pathway and its relation with arousal and respiratory reactivity BRAVE

2025-524511-36-00 · tracked via the Priya Life Science EU tracker
Sponsor
Hospices Civils De Lyon
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Nervous System Diseases
Decision date
30/04/2026
Enrollment target
50
Sites
France

Condition studied

Neurology

Investigational medicinal product(s)

[18F]CPFPX

Eligibility

Age group
18-64 years
Sex
Female, Male

Primary endpoint

Comparison of the [18F]-CPFPX BPND in the brainstem structures involved in respiratory regulation under hypercapnic condition in patients with drug-resistant epilepsy with the one of healthy subjects

Endpoint detail

Comparison of the [18F]-CPFPX BPND in the cortical structures involved in respiratory regulation under hypercapnic condition in patients with drug-resistant epilepsy with the one of healthy subjects, Evaluating the relation between [18F]-CPFPX BPND in the brainstem structures involved in respiratory regulation under hypercapnic condition and the HCVR slope in patients with drug-resistant epilepsy and in healthy subjects, Comparison of the HCVR slope in patients with drug-resistant epilepsy and in heathly subjects, Evaluating the relation between the HCVR slope and the pattern of BOLD activiation during BH in patients with drug-resistant epilepsy and in heathly subjects, Comparing brainstem regional volumes on MRI of patients with drug-resistant epilepsy with the one of healthy subjects, Evaluating the relation between the brainstem regional volumes on MRI and the HCVR slope in patients with drug-resistant epilepsy and in heathly subjects, Evaluating the relation between mean daily intake of caffeine (mg/day) and the [18F]-CPFPX BPND in the brainstem and cortical structures

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524511-36-00 on CTIS ↗ ← All trials in the EU